Postherpetic Neuralgia - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Postherpetic Neuralgia - Pipeline Review, H1 2016', provides an overview of the Postherpetic Neuralgia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Postherpetic Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Postherpetic Neuralgia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Postherpetic Neuralgia - The report reviews pipeline therapeutics for Postherpetic Neuralgia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Postherpetic Neuralgia therapeutics and enlists all their major and minor projects - The report assesses Postherpetic Neuralgia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Postherpetic Neuralgia Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Postherpetic Neuralgia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Postherpetic Neuralgia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Postherpetic Neuralgia Overview 9 Therapeutics Development 10 Pipeline Products for Postherpetic Neuralgia - Overview 10 Postherpetic Neuralgia - Therapeutics under Development by Companies 11 Postherpetic Neuralgia - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Unknown Stage Products 16 Postherpetic Neuralgia - Products under Development by Companies 17 Postherpetic Neuralgia - Companies Involved in Therapeutics Development 18 Aestus Therapeutics, Inc. 18 ContraVir Pharmaceuticals, Inc. 19 Daewoong Pharmaceutical Co., Ltd. 20 Daiichi Sankyo Company, Limited 21 Immune Pharmaceuticals Inc. 22 Kineta, Inc. 23 Merck & Co., Inc. 24 Pfizer Inc. 25 Phosphagenics Limited 26 Purdue Pharma L.P. 27 Relmada Therapeutics, Inc. 28 Scilex Pharmaceuticals, Inc. 29 Teva Pharmaceutical Industries Ltd. 30 Toray Industries, Inc. 31 Postherpetic Neuralgia - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Combination Products 33 Assessment by Target 34 Assessment by Mechanism of Action 37 Assessment by Route of Administration 39 Assessment by Molecule Type 41 Drug Profiles 43 (amitriptyline + ketamine hydrochloride) - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 (clonidine hydrochloride + naltrexone hydrochloride) - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 ATX-08001 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 bupivacaine hydrochloride - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 C-746 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 CNV-2197944 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 DWP-05195 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Flexicaine Peel - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 funapide - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 FV-100 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 ketoprofen - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 lidocaine hydrochloride - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 lidocaine hydrochloride patch - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 mepivacaine hydrochloride - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 mirogabalin besylate - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 MK-8291 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 naltrexone hydrochloride - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 NXN-462 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 pregabalin CR - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 TRK-700 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 U-2902 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 V-116517 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 zucapsaicin - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Postherpetic Neuralgia - Recent Pipeline Updates 74 Postherpetic Neuralgia - Dormant Projects 84 Postherpetic Neuralgia - Discontinued Products 86 Postherpetic Neuralgia - Product Development Milestones 87 Featured News & Press Releases 87 Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study 87 Dec 10, 2015: SCILEX Pharmaceuticals Announces Executive Hires 87 Sep 16, 2015: FDA Accepts SCILEX Pharmaceuticals' NDA Filing for ZTlido 88 Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial 88 Apr 02, 2015: Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia 88 Feb 20, 2015: ContraVir Pharmaceuticals Provides Clinical Update on FV-100 89 Feb 19, 2015: Xenon Pharmaceuticals Partner Teva to Initiate Phase 2b Clinical Trial of TV-45070 in Post-Herpetic Neuralgia 89 Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin 90 Jan 07, 2015: ContraVir Pharmaceuticals Granted FDA Meeting to Discuss Proposal for Phase 3 Trial of FV-100 91 Dec 18, 2014: Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia 91 Appendix 93 Methodology 93 Coverage 93 Secondary Research 93 Primary Research 93 Expert Panel Validation 93 Contact Us 93 Disclaimer 94
List of Tables
Number of Products under Development for Postherpetic Neuralgia, H1 2016 10 Number of Products under Development by Companies, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Comparative Analysis by Unknown Stage Development, H1 2016 16 Products under Development by Companies, H1 2016 17 Postherpetic Neuralgia - Pipeline by Aestus Therapeutics, Inc., H1 2016 18 Postherpetic Neuralgia - Pipeline by ContraVir Pharmaceuticals, Inc., H1 2016 19 Postherpetic Neuralgia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 20 Postherpetic Neuralgia - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 21 Postherpetic Neuralgia - Pipeline by Immune Pharmaceuticals Inc., H1 2016 22 Postherpetic Neuralgia - Pipeline by Kineta, Inc., H1 2016 23 Postherpetic Neuralgia - Pipeline by Merck & Co., Inc., H1 2016 24 Postherpetic Neuralgia - Pipeline by Pfizer Inc., H1 2016 25 Postherpetic Neuralgia - Pipeline by Phosphagenics Limited, H1 2016 26 Postherpetic Neuralgia - Pipeline by Purdue Pharma L.P., H1 2016 27 Postherpetic Neuralgia - Pipeline by Relmada Therapeutics, Inc., H1 2016 28 Postherpetic Neuralgia - Pipeline by Scilex Pharmaceuticals, Inc., H1 2016 29 Postherpetic Neuralgia - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 30 Postherpetic Neuralgia - Pipeline by Toray Industries, Inc., H1 2016 31 Assessment by Monotherapy Products, H1 2016 32 Assessment by Combination Products, H1 2016 33 Number of Products by Stage and Target, H1 2016 35 Number of Products by Stage and Mechanism of Action, H1 2016 38 Number of Products by Stage and Route of Administration, H1 2016 40 Number of Products by Stage and Molecule Type, H1 2016 42 Postherpetic Neuralgia Therapeutics - Recent Pipeline Updates, H1 2016 74 Postherpetic Neuralgia - Dormant Projects, H1 2016 84 Postherpetic Neuralgia - Dormant Projects (Contd..1), H1 2016 85 Postherpetic Neuralgia - Discontinued Products, H1 2016 86
List of Figures
Number of Products under Development for Postherpetic Neuralgia, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Assessment by Monotherapy Products, H1 2016 32 Assessment by Combination Products, H1 2016 33 Number of Products by Top 10 Targets, H1 2016 34 Number of Products by Stage and Top 10 Targets, H1 2016 34 Number of Products by Top 10 Mechanism of Actions, H1 2016 37 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 37 Number of Products by Routes of Administration, H1 2016 39 Number of Products by Stage and Routes of Administration, H1 2016 39 Number of Products by Molecule Types, H1 2016 41 Number of Products by Stage and Molecule Types, H1 2016 41
Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous industRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected toRead More...
Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehiRead More...
Global outsourced customer care services market is projected to reach USD 84.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Swelling need for interaction through non-voice channels is estimated to boost global demand over tRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.